2. Disease Areas
  3. Cancer Digestive System Disease
  4. Digestive System Cancer
  5. Colorectal Cancer

Colorectal Cancer

Colorectal cancer is the third most common malignancy in the United Kingdom, with around 34,000 new cases diagnosed annually, and exhibits a 5-year survival rate between 63% and 73%. It arises from abnormal cell growth in the colon or rectum, most commonly as adenocarcinoma, and often develops from precancerous polyps. The liver is the most frequent site of recurrence after curative surgery. Risk factors include age over 45, genetic predisposition, lifestyle factors, and inflammatory bowel disease. Early-stage disease may be asymptomatic, but symptoms such as altered bowel habits, blood in stool, abdominal pain, and unexplained weight loss may occur as it progresses. Screening methods like colonoscopy are vital for early detection and prevention. The disease is characterized by molecular alterations including chromosomal instability, and treatment strategies vary by stage, ranging from surgery for early cases to systemic therapies for advanced disease. Colorectal cancer remains one of the most prevalent cancers globally, underscoring the importance of awareness, screening, and timely intervention.

References:

Colorectal Cancer (2196):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10219
    Rapamycin 53123-88-9 99.94%
    Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
    Rapamycin
  • HY-10431
    SB-431542 301836-41-9 99.85%
    SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.
    SB-431542
  • HY-10108
    LY294002 154447-36-6 99.95%
    LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively. LY294002 also inhibits CK2 with an IC50 of 98 nM. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. LY294002 is an apoptosis activator.
    LY294002
  • HY-12318
    IBMX 28822-58-4 99.99%
    IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC50s of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and PDE5, respectively.
    IBMX
  • HY-10999
    Trametinib 871700-17-3 99.93%
    Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis.
    Trametinib
  • HY-11102
    RO4929097 847925-91-1 99.01%
    RO4929097 (RG-4733) is an orally active γ secretase inhibitor with an IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively.
    RO4929097
  • HY-171616
    DCEM1 878949-21-4 99.31%
    DCEM1 binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 with ClpP, thereby blocking the mitochondrial unfolded protein response. DCEM1 inhibits β-catenin expression and ATP production in PC-3 and TKO cells. DCEM1 can be used in prostate cancer research.
    DCEM1
  • HY-174275
    TEAD1/3/4-IN-1 2762619-63-4 99.04%
    TEAD1/3/4-IN-1 (compound 1) is a TEAD1/3/4 inhibitor that inhibits YAP/TAZ-TEAD interaction and can be used in cancer research.
    TEAD1/3/4-IN-1
  • HY-B0627
    Metformin 657-24-9 99.98%
    Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
    Metformin
  • HY-100523
    ML385 846557-71-9 99.95%
    ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor with an IC50 of 1.9 μM.
    ML385
  • HY-10201
    Sorafenib 284461-73-0 99.91%
    Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator.
    Sorafenib
  • HY-15772
    Osimertinib 1421373-65-0 99.96%
    Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
    Osimertinib
  • HY-13027
    DAPT 208255-80-5 99.97%
    DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.
    DAPT
  • HY-18085
    Quercetin 117-39-5 99.80%
    Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.
    Quercetin
  • HY-10358
    MK-2206 dihydrochloride 1032350-13-2 99.99%
    MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active, BBB-penetrated allosteric AKT inhibitor with IC50s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy.
    MK-2206 dihydrochloride
  • HY-B0146
    Verteporfin 129497-78-5 99.58%
    Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis. Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation.
    Verteporfin
  • HY-100381
    Nigericin sodium salt 28643-80-3 99.37%
    Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.
    Nigericin sodium salt
  • HY-10254
    Mirdametinib 391210-10-9 99.95%
    Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts.
    Mirdametinib
  • HY-114277
    Sotorasib 2296729-00-3 99.75%
    Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC).
    Sotorasib
  • HY-10981
    Lenvatinib 417716-92-8 99.75%
    Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
    Lenvatinib